Crispr Therapeutics, which trades under the ticker CRSP on Nasdaq, is leading the charge in the field of gene-editing technology, with a focus on developing groundbreaking treatments for serious health conditions.
The company has recently reached a pivotal moment with the approval of Casgevy, marking the world’s first CRISPR-based therapy designed to treat sickle cell disease and beta thalassemia. CRISPR stands for “clustered regularly interspaced short palindromic repeats,” a genetic sequence that influenced the company’s name.
In addition to Casgevy, Crispr Therapeutics has a wide-ranging pipeline that includes five clinical programs and ten preclinical ones.
Over the past year, Crispr’s stock has seen significant volatility. It surged from under $40 in late 2023 to nearly $90 by early 2024, only to plummet thereafter.
Presently, the stock hovers around $40, having lost more than 50% from its peak. This decline mirrors investors’ concerns about the company’s profitability path despite its leading-edge technology.
Financially, Crispr Therapeutics is still in the early stages of commercializing its products. The company has invested heavily in R&D while expanding its pipeline into four therapeutic areas: hemoglobinopathies, a CAR-T immune cell therapy, in vivo strategies, and Type 1 diabetes treatments.
With around $1.9 billion in cash, Crispr has the means to further its clinical programs, though substantial revenue will likely be limited until Casgevy and other treatments are more widely accepted in the market.
Evaluating Crispr Therapeutics through the Value Meter framework reveals intriguing insights. The company’s enterprise value-to-net asset value (EV/NAV) ratio is 0.97, suggesting investors might acquire all of Crispr’s assets slightly below their book value—a notable opportunity compared to the average EV/NAV of 7.89 among similar firms.
Nevertheless, Crispr’s cash flow presents a different narrative. Its free cash flow-to-net asset value (FCF/NAV) ratio is -2.52%, having produced negative free cash flow in three of the past four quarters. This is marginally worse than the average of -2.23% for companies facing similar cash flow challenges.
Crispr’s stock price appears to reflect both the vast potential and the daunting risks as it endeavors to turn its scientific innovations into commercial triumphs.
Although the company’s avant-garde tech, diverse pipeline, and appealing EV/NAV suggest promise, its negative cash flow and earnings temper expectations. Consequently, like the Value Meter system, I remain cautious in labeling this stock as undervalued.
The Value Meter concludes that Crispr Therapeutics is “Appropriately Valued.”
If there’s another stock you’d like assessed using The Value Meter, please let me know.
